Balyasny Asset Management
SPRB

Balyasny Asset Management’s Spruce Biosciences SPRB Stock Holding History

Balyasny Asset Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Sell
12,138
-27,862
-70% -$1.56M ﹤0.01% 2409
2026
Q1 		$2.61M Hold
40,000
– – ﹤0.01% 1670
2025
Q4 		$3.48M Buy
+40,000
New +$4.29M ﹤0.01% 1583
2024
Q2 		– Sell
-300
Closed -$17.7K – 3219
2024
Q1 		$17.7K Buy
+300
New +$76.3K ﹤0.01% 2541

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Balyasny Asset Management's SPRB Position: Q2 2026 in Review

Balyasny Asset Management reduced its Spruce Biosciences (SPRB) stake by 70% in Q2 2026, selling an estimated $1.56M and leaving 12,138 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

Balyasny Asset Management first reported a position in SPRB in Q1 2024 and has held it in 4 quarters since. The position peaked at $3.48M in Q4 2025. 64 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Balyasny Asset Management held 12,138 shares of Spruce Biosciences worth $655K as of Q2 2026.
  • Balyasny Asset Management sold 27,862 Spruce Biosciences shares in Q2 2026, an estimated $1.56M.
  • Spruce Biosciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2409 holding.
  • Balyasny Asset Management first reported a position in Spruce Biosciences in Q1 2024 and has held it in 4 quarters since.
  • Balyasny Asset Management's Spruce Biosciences position peaked at $3.48M in Q4 2025.
  • 64 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.